Navigation Links
GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
Date:11/10/2008

ATLANTA, Nov. 10 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) ("GeoVax" or "the Company"), a biopharmaceutical firm developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced its third quarter 2008 financial results and provided an operational update.

Robert McNally, GeoVax's President and CEO, commented, "We are very pleased with the progress we've made during the third quarter of 2008 and for the year so far, as we've taken steps to address both short-term and long-term goals. We made a shipment of the vaccine to the HIV Vaccine Trials Network during October, which is a significant step in preparation for the largest clinical trial yet to be undertaken by GeoVax and we look forward to HVTN's initiation of the Phase 2a trial later this year. We are also nearing completion of a license with Vivalis S.A., a French biopharmaceutical company, for manufacturing platform technology for the MVA portion of our vaccine that we anticipate will significantly improve the long-term production capabilities for the vaccine."

Financial Results for the Three Months and Nine Months Ended September 30, 2008

The Company recorded a net loss of $722,108 for the three months ended September 30, 2008, compared to $1,165,519 for the same period in 2007. For the nine months ended September 30, 2008, the Company's net loss was $2,688,970 as compared to $3,085,926 in 2007. Net losses for 2008 were partially offset by grant revenues of $1,322,502 and $2,298,571 for the three month and nine month periods, respectively, related to the Company's grant from the National Institutes of Health (NIH) in support of its HIV/AIDS vaccine development activities. As of September 30, 2008, the Company reported cash balances totaling $2,784,706.

Summarized financial information is attached. Further information concerning the Company's financial position and results of operation
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Further Strengthens Management Team
4. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
5. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
6. GeoVax Presents Data at AIDS Vaccine 2008 Conference
7. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... 26, 2014 Genedata, a leading ... and life science research, today announced the ... be held in Asia, Europe, and North America ... companies and leading research organizations will gather for ... case studies, and upcoming challenges in all areas ...
(Date:8/26/2014)... CITY, Calif. , Aug. 26, 2014 /PRNewswire/ ... development and commercialization of oncology diagnostic products, has ... as a 2015 Technology Pioneer . As ... is one of 24 companies across a wide ... prestigious accolade. Guardant360 ® , ...
(Date:8/26/2014)... Cary, NC (PRWEB) August 26, 2014 ... built-in GMP processes, implemented a new pricing structure with ... better comply with cGMP and 21 CFR Part 11 ... Good Manufacturing Practices any way we can” said Rick ... the number of available users allowed customers to have ...
(Date:8/26/2014)... 26, 2014 Historically, drug development ... list continues to grow – high attrition rate, ... and development, high regulatory hurdles and increasing ... become clear that the traditional business model of ... are now seeking to find better ways to ...
Breaking Biology Technology:Thought Leaders to Explore Innovations in SPR & Combination Screening at Genedata Screener User Group Meetings 2Thought Leaders to Explore Innovations in SPR & Combination Screening at Genedata Screener User Group Meetings 3Guardant Health Named a 2015 Technology Pioneer by World Economic Forum 2Transitioning from Bench into Clinical Phase, new webinar hosted by Xtalks 2
... Verenium Corporation (Nasdaq: VRNM ), a ... today announced that it has entered into an agreement ... United States ("Ex-Im Bank") for two 18-month, secured revolving ... These new credit facilities will allow the Company ...
... 2011 PharmaVentures today announced the launch of ... Essential Deal Trends: Oncology 2011 . This new series ... and commercialising new drugs. The first report in the series ... active deal making therapeutic area in the pharmaceutical and biotechnology ...
... cell carcinomas are amongst the most frequent cancers in ... like many other human cancers, contain particular cancer cells, ... potential that sustain tumor growth. Little is known about ... High level of VEGF expression in skin cancer ...
Cached Biology Technology:Verenium Announces Up to $16 Million in New Secured Financings 2Verenium Announces Up to $16 Million in New Secured Financings 3Pfizer, Sanofi and Genentech Feature Prominently in the Oncology Edition of PharmaDeals' New Publication Series; Essential Deal Trends 2Pfizer, Sanofi and Genentech Feature Prominently in the Oncology Edition of PharmaDeals' New Publication Series; Essential Deal Trends 3New role for Vascular Endothelial Growth Factor in regulating skin cancer stem cells 2
(Date:8/25/2014)... Scientists have known that toxic effects of substances ... both natural and human-made materials, can pass from ... shows that females with ancestral exposure to EDC ... According to a new study by researchers from ... State University, male and female rats are affected ...
(Date:8/25/2014)... 133 active fires in the North Slave Region of the ... 24 hours. Fire danger is moderate to high. Smoke ... Lake Complex of fires are in an area approximately 80 ... north of Fort Providence. Four crews will be working ... week. Mop-up continues many areas of complex,s fire perimeter. The ...
(Date:8/25/2014)... a lightning strike on August 12, 2014. Currently the ... There are close to 2,000 personnel working on this ... and a number of large ones. Most of the ... 100 acres. An inversion layer settled over the fire ... keeping fire activity moderate. As the inversion lifted in the ...
Breaking Biology News(10 mins):Exposure to toxins makes great granddaughters more susceptible to stress 2Happy Camper and July Fire Complexes in California 2
... Va.Though many policymakers have argued that environmental regulations ... a new study by George Mason University researcher ... production processes can not only offset the costs ... The study, which looked at more than ...
... branch of Munich (Germany) based Genomatix Software GmbH, announced ... to provide Genomatix software and data content to Pfizer ... Pfizer are designed to show how genes are regulated ... the software and data content to help understand the ...
... International,Inc. (OTC Bulletin Board: BKYI), a leader in ... issued the following,open letter to its shareholders discussing ... performance., Highlights:, -- Revenue growth from ... in our installed base of law enforcement customers, ...
Cached Biology News:Corporations can profit from being environmentally friendly 2BIO-key(R) Issues Open Letter to Shareholders 2BIO-key(R) Issues Open Letter to Shareholders 3BIO-key(R) Issues Open Letter to Shareholders 4BIO-key(R) Issues Open Letter to Shareholders 5
...
...
... Formulation: 50mM Tris-HCl, pH 7.5, ... PMSF, 1mM benzamidine, 0.1% 2-mercaptoethanol ... (Protein Phosphatase 2A1) partially purified ... precipitation, QSepharose,amino-hexyl agarose, Superdex 200, ...
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
Biology Products: